{
  "nctId": "NCT02300727",
  "briefTitle": "Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy",
  "officialTitle": "A Phase I/II Study to Determine the Safety and Efficacy of Curcumin in Patients With Oral Mucositis Secondary to Chemotherapy",
  "protocolDocument": {
    "nctId": "NCT02300727",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2015-04-29",
    "uploadDate": "2019-05-09T14:36",
    "size": 329559,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02300727/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE1",
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 6,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-02",
    "completionDate": "2018-10-25",
    "primaryCompletionDate": "2018-10-25",
    "firstSubmitDate": "2014-11-21",
    "firstPostDate": "2014-11-25"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* ≥ grade 2 oral mucositis related to chemotherapy for cancer\n* Ability to understand and the willingness to review and sign a written informed consent document.\n* ≥ 18 years of age\n* Willingness to use adequate contraception prior to study entry, for the duration of study participation and for 30 days after the last dose for women of child-bearing potential and men\n\nExclusion Criteria:\n\n* Current use of therapeutic doses of anticoagulants such as warfarin or antiplatelet agents (prophylactic doses and agents are acceptable)\n* Biliary tract obstruction or cholelithiasis\n* History of gastric or duodenal ulcers or hyperacidity syndromes\n* AST or ALT \\> 2 x ULN\n* Total bilirubin ≥ 2 x ULN\n* INR \\> 1.5\n* Previous stem cell transplant (allogeneic or autologous)\n* Preexisting oral disease, such as active oral infection, trauma to the oral mucosa or oral - ulceration prior to chemotherapy\n* Known allergy/hypersensitivity to curcumin, yellow food coloring, or other members of the - Zingiberaceae (ginger) family\n* Pregnant or breastfeeding",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants With Serious and Non-Serious Adverse Events",
        "description": "Number of Participants with Serious and Non-Serious Adverse Events.",
        "timeFrame": "reviewed weekly for 4 to 6 weeks"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Toxicities Graded by Health Care Providers Using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0",
        "description": "NA - Protocol ended early after failing to enroll sufficiently. Only 6 subjects enrolled, 5 completed, 1 withdrew. Zero participants analyzed.",
        "timeFrame": "Baseline, weekly for 5 to 7 weeks"
      },
      {
        "measure": "Change in Subjective Patient Self-assessment of Pain.",
        "description": "NA - Protocol ended early after failing to enroll sufficiently. Only 6 subjects enrolled, 5 completed, 1 withdrew. Insufficient data to analyze",
        "timeFrame": "Baseline, weekly for 5 to 7 weeks"
      },
      {
        "measure": "Change in Subjective Patient Self- Assessment of Oral Mucositis Measured by the Common Terminology Criteria for Adverse Events (CTCAE) and World Health Organization's (WHO's) Oral Toxicity Scale (OTS)",
        "description": "NA - Protocol ended early after failing to enroll sufficiently. Only 6 subjects enrolled, 5 completed, 1 withdrew. Insufficient data to analyze",
        "timeFrame": "Baseline, weekly for 5 to 7 weeks"
      },
      {
        "measure": "Change in Health Providers Assessment of Oral Mucositis and Healing Time Measured by the Common Terminology Criteria for Adverse Events (CTCAE) and World Health Organization's (WHO's) Oral Toxicity Scale (OTS)",
        "description": "NA - Protocol ended early after failing to enroll sufficiently. Only 6 subjects enrolled, 5 completed, 1 withdrew. Insufficient data to analyze",
        "timeFrame": "Baseline, then weekly for 4 to 6 weeks"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 4,
      "otherCount": 0,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 54,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:51.882Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}